In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability

Andrea Giuffrida, Lance R. McMahon

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

This review focuses on the behavioral pharmacology of endogenous cannabinoids (endocannabinoids) and indirect-acting cannabinoid agonists that elevate endocannabinoid tone by inhibiting the activity of metabolic enzymes. Similarities and differences between prototype cannabinoid agonists, endocannabinoids and inhibitors of endocannabinoid metabolism are discussed in the context of endocannabinoid pharmacokinetics in vivo. The distribution and function of cannabinoid and non-CB1/CB2 receptors are also covered, with emphasis on their role in disorders characterized by dopamine dysfunction, such as drug abuse and Parkinson's disease. Finally, evidence is presented to suggest that FAAH inhibitors lack the abuse liability associated with CB1 agonists, although they may modify the addictive properties of other drugs, such as alcohol.

Original languageEnglish (US)
Pages (from-to)90-103
Number of pages14
JournalProstaglandins and Other Lipid Mediators
Volume91
Issue number3-4
DOIs
StatePublished - Apr 1 2010

Keywords

  • 2-Arachidonyl glycerol
  • Anandamide
  • Cannabinoid
  • Drug abuse
  • Dyskinesia
  • FAAH
  • Levodopa
  • MAGL
  • Marijuana

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Fingerprint Dive into the research topics of 'In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability'. Together they form a unique fingerprint.

  • Cite this